NASDAQ:CLDX
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.'s revenue fell 78.0% in fiscal 2025 to $1.5M while operating margin fell to −18599.8%, its lowest in 10 years. Free cash flow was −$213.7M, −13829.1% of revenue, and the diluted share count rose 3.1%.Summary generated from Celldex Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 25, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.5M
Revenue growth−78.0%
Revenue, 5-yr CAGR−26.9%
Gross margin87.1%
Operating margin−18599.8%
Net margin−16748.0%
ROICn/a
Return on equity−40.6%
Debt / equityn/a
Free cash flow−$213.7M
FCF margin−13829.1%
Share count change+3.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 5 | 2 | 7 | 7 | 2 |
| Operating income | −71 | −115 | −155 | −195 | −287 |
| Net income | n/a | n/a | −141 | −158 | −259 |
| Free cash flow | −62 | −106 | −109 | −160 | −214 |
Recent filings
- 8-KOther events
Sep 22, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KDirector or officer change
Jul 15, 2026 - 4Insider transaction report
Jun 29, 2026 - 4Insider transaction report
Jun 29, 2026 - 8-KDirector or officer change
Jun 26, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026